HMGCR and breast carcinoma: For example, the character of glucose uptake by cancer cells has been successfully explored in clinics through the application of fluorodeoxyglucose positron emission tomography (FDG/PET) imaging to monitor cancers and assess response to therapy [9]; statins, specific hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR) inhibitors, significantly reduce the risk of prostate and breast cancer, and inhibit the progression of certain cancers [10].